| Overview |
| bsm-51694M |
| LEF1 Monoclonal Antibody |
| WB |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| Recombinant human LEF-1 between 95-283 amino acids. |
| Monoclonal |
| F11A3 |
| 0.5ug/ul |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 51176 |
| Q9UJU2 |
| Nucleus |
| lymphoid enhancing factor-1; Transcription factor T cell specific 1 alpha ; DKFZp586H0919; LEF 1; LEF1; Lymphoid enhancer binding factor 1; T cell specific transcription factor 1 alpha; TCF 1 alpha; TCF1 alpha; TCF1alpha; TCF1-alpha; LEF1_HUMAN; Lymphoid enhancer-binding factor 1; T cell-specific transcription factor 1-alpha. |
| Participates in the Wnt signaling pathway. Activates transcription of target genes in the presence of CTNNB1 and EP300. May play a role in hair cell differentiation and follicle morphogenesis. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by LEF1 and CTNNB1. Regulates T-cell receptor alpha enhancer function. Binds DNA in a sequence-specific manner. PIAG antagonizes both Wnt-dependent and Wnt-independent activation by LEF1 (By similarity). Isoform 3 lacks the CTNNB1 interaction domain and may be an antagonist for Wnt signaling. Isoform 5 transcriptionally activates the fibronectin promoter, binds to and represses transcription from the E-cadherin promoter in a CTNNB1-independent manner, and is involved in reducing cellular aggregation and increasing cell migration of pancreatic cancer cells. Isoform 1 transcriptionally activates MYC and CCND1 expression and enhances proliferation of pancreatic tumor cells. |
| Application Dilution |
| WB |
=1:500-2000， |
Powered by Bioz